New Zealand Medical Journal · 20 Nov 2026
Estimating selected screening-related parameters using New Zealand–specific glaucoma prevalence data: optometry visits for glaucoma screening at age 45 years
Graham Wilson, Nick Wilson
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
background: Regular eye examinations for glaucoma at age 45 years and every 5 years after have been promoted in the New Zealand setting. We aimed to estimate selected screening-related parameters for optometry visits for glaucoma screening at age 45 years. methods: Selected glaucoma screening parameters were identified from the literature, and data were extracted from a New Zealand longitudinal study (Dunedin Study) on the prevalence of glaucoma in 45-year-olds. Out-of-pocket costs were estimated from New Zealand optometry assessment fees. results: We estimate that routine screening for glaucoma within a New Zealand cohort of 45-year-olds has a low positive predictive value of 5.4%. That is, for every 100 people who get a positive screening result for glaucoma, around 95 of these diagnoses would be expected to be false positives and only five would truly have glaucoma. The number needed to screen to detect one case of glaucoma was estimated at 177. The out-of-pocket cost per true case of glaucoma detected was around NZ$24,300, equivalent to NZ$5.8 million at the national level to detect 241 true cases per year (assuming 70% uptake). However, there would be many other additional costs likely with any formal screening programme encompassing the full clinical pathway. conclusion: These New Zealand–specific findings for selected screening parameters align with recommendations from international agencies showing that there is a lack of evidence in favour of population screening for glaucoma. Future research could focus on evaluating more targeted screening or risk-based screening, e.g., using artificial intelligence–assisted fundus imaging.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.